Evidence for benefits and risks of tadalafil as a non-prescription medicine: review and evaluation using the Group Delphi technique to achieve consensus amongst clinical experts

An evidence-based consensus meeting was held with urologists, a pharmacist and a cardiologist to perform a structured benefit-risk analysis of reclassifying tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor for treatment of erectile dysfunction (ED), to be available without prescription in Germ...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Kurt Miller, Uwe May, Wolf-Dietrich Beecken, Georgios Hatzichristodoulou, Michael Böhm, Stefan Fink
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-10-01
Subjects:	erectile dysfunction non-prescription phosphodiesterase type 5 inhibitor (PDE5 inhibitor) reclassification tadalafil
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1254706/full